Business Context and Reporting Period
Cormedix Inc. filed this Form 8-K on January 3, 2019, reporting events occurring on December 31, 2018. The company, incorporated in Delaware, is focused on the development of its NeutrolinAE program.
Key Financial Metrics and Capital Structure
- Debt Issuance: Entered into a senior secured convertible note with an aggregate principal amount of $7,500,000.
- Proceeds: Gross proceeds of $7,500,000 were received from the sale of the note and warrant.
- Interest Rate: The note bears interest at 10.0% per annum, compounded quarterly.
- Maturity: The note matures on December 30, 2021.
- Warrant Issuance: Issued a warrant to purchase up to 450,000 shares of common stock with an exercise price of $1.50 per share and a five-year term.
- Security: The note is a senior, secured obligation guaranteed by all of the company's assets.
Material Changes and Related Agreements
Simultaneously with the note issuance, Cormedix amended and restated existing warrants held by Elliott Associates, L.P. and its affiliates:
- Reduced the exercise price of 500,000 warrants (issued May 2013) from $0.65 to $0.001 per share.
- Reduced the exercise price of 750,000 warrants (issued October 2013) from $0.90 to $0.001 per share.
Additionally, the company and Elliott Associates agreed to waive conversion or exercise rights for Series C-2, D, E, and F preferred stock and warrants covering 4,014,859 shares of common stock until the earliest of: an amendment to increase authorized shares, a reverse stock split, a Fundamental Transaction, or April 30, 2019.
Guidance, Outlook, and Use of Proceeds
Management intends to use the net proceeds primarily for the NeutrolinAE development program, including clinical trials, research and development expenses, and general and administrative expenses. The filing does not provide specific revenue guidance or profit outlooks, as the company is in a development phase.
Investor Verification Checklist
- Verify the terms of the Senior Secured Convertible Note (Exhibit 4.4), specifically the conversion price of $1.50 and the automatic conversion trigger (150% of conversion price).
- Confirm the dilution impact of the new warrant (450,000 shares) and the amended warrants (1,250,000 shares at $0.001 exercise price).
- Review the waiver agreement regarding Elliott Derivative Securities to understand restrictions on share issuance until April 30, 2019.
- Assess the company's liquidity position post-transaction, noting the $7.5 million cash inflow against the 10% interest obligation.
- Check for any subsequent filings regarding the increase of authorized shares or reverse stock splits, which would lift the conversion waiver.